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Abstract
Background: Pancreatic cancer is the fourth leading cause of cancer death in the United States. Surgery offers the
only chance for cure. However, less than twenty percent of patients are considered operative candidates at the
time of diagnosis. A common reason for being classified as unresectable is advanced loco-regional disease.
A review of the literature indicates that almost nine hundred patients with pancreatic cancer have received
regional chemotherapy in the last 15 years. Phase I studies have shown regional administration of chemotherapy
to be safe. The average reported response rate was approximately 26%. The average 1-year survival was 39%, with
an average median survival of 9 months. Of the patients that experienced a radiographic response to therapy,
78 (78/277, 28%) patients underwent exploratory surgery following regional chemotherapy administration;
thirty-two (41%) of those patients were amenable to pancreatectomy. None of the studies performed analyses to
identify factors predicting response to regional chemotherapy.
Progressive surgical techniques combined with current neoadjuvant chemoradiotherapy strategies have already
yielded emerging support for a multimodality approach to treatment of advanced pancreatic cancer.
Intravenous gemcitabine is the current standard treatment of pancreatic cancer. However, >90% of the drug is
secreted unchanged affecting toxicity but not the cancer per se. Gemcitabine is converted inside the cell into its
active drug form in a rate limiting reaction. We hypothesize that neoadjuvant regional chemotherapy with
continuous infusion of gemcitabine will be well tolerated and may improve resectability rates in cases of locally
advanced pancreatic cancer.
Design: This is a phase I study designed to evaluate the feasibility and toxicity of super-selective intra-arterial
administration of gemcitabine in patients with locally advanced, unresectable pancreatic adenocarcinoma. Patients
considered unresectable due to locally advanced pancreatic cancer will receive super-selective arterial infusion of
gemcitabine over 24 hours via subcutaneous indwelling port. Three to six patients will be enrolled per dose
cohort, with seven cohorts, plus an additional six patients at the maximum tolerated dose; accrual is expected to
last 36 months. Secondary objectives will include the determination of progression free and overall survival, as well
as the conversion rate from unresectable to potentially resectable pancreatic cancer.
Trial Registration: ClinicalTrials.gov ID: NCT01294358
Background
In 2010 there were an estimated 43,140 new cases and
36,800 deaths attributed to pancreatic cancer in the Uni-
ted States [1]. Overall, survival is poor, with approxi-
mately 23% of patients living 12 months after diagnosis.
Overall 5-year survival is approximately 5% at best [2].
Prolonged survival is possible for patients that undergo
complete resection and approximates a median of 18 to
20 months in large series, with or without the addition
of single-agent chemotherapy [3]. Unfortunately, less
than 20% of patients with pancreatic cancer are consid-
ered resectable at the time of diagnosis, most often due
to locally advanced or metastatic disease. For patients
with inoperable pancreatic cancer chemotherapy may
prolong survival and improve quality of life, yet it must
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cal treatment option [4].
Since the 1950s, regional administration of che-
motherapy has been evaluated in many cancers and in
some cases proven an effective therapy for local and
regional disease. The pharmacologic rationale for regio-
nal drug delivery is to increase drug concentrations at
tumor sites and limit systemic drug exposure and its
sequelae [5]. In 1958 Creech et al. described the use of
regional isolation perfusion with nitrogen mustard com-
pounds in the treatment of 24 patients with a variety of
cancers [6]. This report was the first to employ the use
of an extracorporeal circuit in the administration of
regional chemotherapy. Since that time, the role of
regional chemotherapy administration as an adjunctive
therapy in patients with locally advanced or regional dis-
ease has been well established. Regional administration
of chemotherapy is used to treat local-regional and
metastatic disease for many cancer histologies. Examples
of effective regional therapy include isolated limb perfu-
sion, hyperthermic intraperitoneal chemotherapy,
intrathecal, and intravesicular chemotherapy [7-11]. The
Surgery Branch of the National Cancer Institute has
accumulated significant experience over the years with
limb perfusion, peritoneal perfusion, and liver perfusion.
A comprehensive search of the Medline database was
performed by the authors to identify all published
reports of regional therapy for pancreatic cancer in the
English language literature (manuscript in preparation).
Medical subject heading (MeSH) terms used included:
pancreatic neoplasms; infusions, intra-arterial; che-
motherapy, cancer, regional perfusion. Case reports,
dose-escalation trials, and studies of adjuvant regional
chemotherapy alone were excluded. Reports including
multiple gastrointestinal histologies were included only
if the patients with pancreatic cancer diagnoses were
clearly identified and data amenable to separate analysis.
Data collected included the year of publication, size of
series, patient demographics, pathologic details including
UICC (International Union Against Cancer) stage, type
of regional therapy, toxicity and complications, response
rate, and survival rate when available. Instances in
which institutions published updated patient data or
combined analyses, the most recent publications were
used.
Twenty-one reports published between 1995 and Janu-
ary 2010, described 895 patients with pancreatic cancer
treated with regional chemotherapy. The majority of
these studies were small series or sequential, uncon-
trolled trials. The majority of the patients (>95%) were
diagnosed with pancreatic ductal adenocarcinoma. Vir-
tually all patients were described as having locally
advanced (stage III) or metastatic cancer (stage IV) at
the time of treatment. In over half of reports (11/21)
patients were allowed to have undergone prior curative
or palliative surgery and, in studies in which it was
reported, 11% of patients (59/543) received radiation or
chemotherapy prior to receiving regional chemotherapy.
One year survival rates approximated those seen with
systemic chemotherapy. Unfortunately, the analysis of
heterogeneous reports of a non-standardized treatment
strategy is limited not only by the inherent bias asso-
ciated with each study, but also the retrospective nature
of any such review. Despite these limitations, a review of
t h ee x i s t i n gl i t e r a t u r eo na n experimental method of
treating this lethal disease is necessary for the advance-
ment of future investigation.
The primary endpoints reported in most of the studies
described above were tumor response and survival.
World Health Organization (WHO) criteria for objective
tumor response were used by 71% (15/21) of studies,
while 19% (4/21) cited no objective criteria. The average
response rate reported was 25.9% (n = 19 studies). The
average 1-year survival was 38.9% (n = 10), with an
average median survival of 9 months (n = 18). The most
commonly reported toxicities were hematologic and gas-
trointestinal, however 7 studies that reported toxicity
did not use standardized reporting criteria. In total,
there were 199 cases of grade 1-2, and 47 cases of grade
3-4 gastrointestinal toxicity; 142 cases of grade 1-2 and
70 cases of grade 3-4 hematologic toxicity. At least two
studies reported instances of duodenal ulceration while
others reported complications including arterial dissec-
tion, catheter dislocation, inguinal hematoma, lymphatic
fistula, and deep vein thrombosis. Based on radiographic
responses to therapy, 78 out of 277 patients (28%) were
taken to surgery following regional chemotherapy
administration; thirty-two (41%) of those patients were
amenable to pancreatectomy or necrosectomy. There
were no complete responses to regional chemotherapy
reported. No studies performed analyses to identify fac-
tors predicting response to regional chemotherapy. Also,
no studies compared survival of responding patients ver-
sus non-responding patients.
Regional chemotherapy techniques used in these
twenty-one studies included arterial infusion and perfu-
sion, with or without hemofiltration. Celiac axis infusion
(CAI) was used in a majority of studies (57.1%) whereas
selective arterial infusion (SAI; 23.8%) and hypoxic
abdominal perfusion (HAP: 28.6%) were used less often.
In two studies, HAP and CAI were utilized sequentially.
In an attempt to direct blood flow to tumor or pancreas
only, three studies utilized selective arterial embolization
prior to arterial infusion. Variations to arterial catheteri-
zation, including percutaneous versus open surgical
approach, appeared to reflect changes in experience or
the use of newer technologies over time. A variety of che-
motherapeutic agents were used alone or in combination;
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cin-C (MMC; 47.6%), cisplatinum (CDDP; 38.1%), gemci-
tabine (23.8%), mitoxantrone (19%), epirubicin and
carboplatin (14.3%), methotrexate (4.8%) and melphalan
(4.8%). Three studies also included adjuncts to che-
motherapy: warfarin, angiotensin-II, and degradable
starch microspheres.
Rationale for gemcitabine
Gemcitabine is a pro-drug that requires intracellular
phosphorylation for conversion to the active difluoro-
deoxycytidine disphosphate (dFdCDP) and triphosphate
(dFdCTP) metabolites. dFdCTP competes with dCTP
for incorporation into DNA by DNA polymerase; once
incorporated into DNA, dFdCTP is resistant to removal
within the DNA strand by DNA polymerase resulting in
DNA fragmentation and apoptosis. Additionally,
dFdCTP competitively inhibits DNA polymerase resulting
in a decrease in intracellular dCTP and preferential incor-
poration of dFdCTP into DNA (referred to as self-poten-
tiation). The pharmacokinetics of dFdCTP are linear;
however, the phosphorylation and metabolism of dFdCTP
are saturable at dose rates above 10 mg/m
2/min [12]. This
observation suggests that perhaps smaller doses given over
longer period of time may potentiate the cytotoxic effect
of gemcitabine. Indeed providing proof of this principle,
Tempero et al. reported improved median survival (5.0 vs.
8.0 mo; p = 0.013) and 2-yr survival rates (2.2% vs. 18.3%;
p = 0.007) when comparing the recommended dose of sin-
gle agent gemcitabine 1000 mg/m
2 given as a 30-minute
infusion weekly, compared with a fixed dose rate (FDR)
infusion given at 10 mg/m
2/min (1500 mg/m
2 over
150 minutes) [13,14].
Based on the pharmacology of gemcitabine described
above, two studies reported on prolonged administra-
tion of gemcitabine. Anderson et al. reported on a
phase-I study of a 24 hour infusion of gemcitabine in
previously untreated patients with inoperable non-
small-cell lung cancer. A total of 24 patients were stu-
died. Gemcitabine was administered intravenously as a
24-hour infusion on days 0, 7 and 14 every 28 days.
Dose levels were 10, 20, 40, 80, 120, 180, and 210 mg/
m
2/24 hr. The maximum tolerated dose (MTD) was
180 mg/m
2/24 hr and the dose limiting toxicity (DLT)
was neutropenia and lethargy [15]. Rajdev et al.
reported on a phase-I trial of gemcitabine administered
as a 96-hour continuous intravenous infusion in
patients with advanced carcinoma and lymphoma.
Gemcitabine was initially given at 1 mg/m
2/24 hr for
48 hours, then 72 hours and finally 96 hours [16]. The
dose was then increased to 2, 4, 6, 10, 15, 20 and
25 mg/m
2/24 hr for 96 hours. Thirty four patients
were treated with a variety of tumors. The MTD was
8m g / m
2/24 hr for 96-hour infusions given every
3w e e k sa n d6m g / m
2/24 hr for 96-hour infusions
given every 2 weeks. The most common grade 2 or
higher toxicity at all dose levels included fever, dys-
pnea, mucositis hypotension, nausea, vomiting, and
fatigue. Neutropenia and thrombocytopenia were
uncommon.
In summary, greater than 80% of patients with pan-
creatic cancer have unresectable primary tumors at the
time of diagnosis, most often due to locally advanced
disease. This represents a significant proportion of
patients with a small chance for meaningful survival at
5-years. The application of local-regional chemotherapy
for advanced pancreatic cancer has been posited not
only as a method of effectively treating locally advanced
disease, but also as a means of transforming a previously
unresectable tumor into a resectable one, thereby poten-
tially improving long-term survival. Therefore, a pro-
spective phase I study has been designed to evaluate the
safety and efficacy of selective regional infusion of gem-
citabine in patients with locally advanced, unresectable
pancreatic cancer.
Methods
The Regional Chemotherapy in Locally Advanced Pan-
creatic Cancer (RECLAP) Trial was approved by the
Institutional Review Board (IRB) of the National Cancer
Institute, National Institutes of Health, Bethesda, Mary-
land, USA.
Design
This study is a phase I trial with inter-patient and
intra-patient dose escalation scheme in which cohorts
of patients will be treated with increasing doses of
gemcitabine administered as a super-selective continu-
ous arterial infusion over 24 hours. The trial schema is
illustrated in Figure 1. The study will be performed at
the Clinical Center of the NIH by the Surgery Branch,
NCI in Bethesda, Maryland, USA. Patients who have
been diagnosed with unresectable, locally advanced
pancreatic cancer will be enrolled. The diagnosis must
be histologically or cytologically confirmed as pancrea-
t i ca d e n o c a r c i n o m aw i t hn oe x t r a - p a n c r e a t i cd i s e a s e
except regional lymph nodes. The disease should be
deemed resectable by previously published and
accepted criteria for surgical resection [17]. Patients
may have previously received chemotherapy and/or
radiation therapy.
Dose-escalation and limiting toxicity
The starting dose of cohort 1 (3 patients) will be 18 mg/
m
2/24 hr, which is 10% of the 24-hour systemic infusion
gemcitabine dose. The maximum tolerated dose is the
highest dose that induces dose limiting toxicity in no
more than 1 patient among a cohort of 6 patients.
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dosing at successively higher doses until MTD is estab-
lished, or up to 165 mg/m
2/24 hr.
-Cohort 1: 18 mg/m
2/24 hr
-Cohort 2: 36 mg/m
2/24 hr
-Cohort 3: 72 mg/m
2/24 hr
-Cohort 4: 96 mg/m
2/24 hr
-Cohort 5: 115 mg/m
2/24 hr
-Cohort 6: 138 mg/m
2/24 hr
-Cohort 7: 165 mg/m
2/24 hr
Patients who complete the first cycle of a course with-
out experiencing any dose limiting toxicities may esca-
late to the next dose level for subsequent cycles.
Patients who escalate to higher dose levels will not
count towards accrual to the higher cohort but will
remain in their initial cohort. The rational for using
intra-patient dose escalation is as follows: Unresectable
locally advanced pancreatic cancer is a deadly disease
without effective therapy; if toxicity is not exhibited by
any particular patient, it is reasonable to assume that
dose escalation is safe. This will afford patients who
start in the early cohorts and do not exhibit toxicity a
potential chance to benefit from the trial by progressing
to a higher dose level. Toxicity data will be derived from
the first dose level and we will analyze the data in terms
of cumulative toxicities.
Data and Safety Monitoring
Careful evaluation to ascertain the toxicity and clinical
response will be performed according to the standard of
care. Any adverse events will be reported daily, assessed
and treated properly by the principal investigator and
clinical research team. Adverse events will be graded
according to the Common Terminology Criteria for
Course 1
C1 W1 dl 1 DLT
yes
no
Dose de-
escalation
Escalate to next
dose level
C2 W4
Evaluation of
response
PR,SD,CR by
RECIST
PD by RECIST or
by clinical exam
Off treatment
C1 W2 rest C1 W3 dl 1 C1 W4 rest
{Tox eval}
C2 W1 dl 2 C2 W2 rest C2 W3 dl 2 C2 W4 rest
{Tox eval}
Course 2 and 3
C1 W1 dl 3 DLT
yes
no
Treat at prior
dose level
Escalate to next
dose level
C2 W4
Evaluation of
response
PD by RECIST or
by clinical exam Off treatment
C1 W2 rest C1 W3 dl 3
C1 W4 rest
{Tox eval} C2 W1 dl 4 C2 W2 rest C2 W3 dl 4
C2 W4 rest
{Tox eval}
C2 W1 dl 3 C2 W2 rest C2 W3 dl 3 C2 W4 rest
{Tox eval}
DLT
yes
no
Treat at prior
dose level
Escalate to next
dose level
DLT
yes
no
Treat at prior
dose level
Escalate to next
dose level
DLT
for
dose
level 1
RECLAP Schema - cohort 1
Resectable no
yes
Off Study Treatment
Surgical Resection
PR,SD,CR by
RECIST
Resectable no
yes
Off Study Treatment
Surgical Resection
Figure 1 RECLAP Trial Schema, Cohort 1. C1 W1 dl1 = Cycle 1, Week 1, dose level 1; C1W3 dl1 = Cycle 1, Week 3, dose level 1, etc.; DLT,
dose limiting toxicity; PD, progressive disease; PR, partial response; SD, stable disease; CR, partial response; RECIST, Response Evaluation Criteria in
Solid Tumors; Subsequent cohorts will follow the same schema of treatment courses.
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toxicity is defined as all grade 3 or greater toxicities
with the exception of grade 3 constitutional symptoms
that persist for less than 72 hours, grade 3 and 4 myelo-
suppression (neutrophils and platelets) of less than
5 days duration, and grade 3 metabolic/laboratory events
that are correctable within 24 hours. Accrual will be sus-
pended, the IRB will be notified, and the dose escalation
regimen will be reassessed if any of the following criteria
are met during the first course (8 weeks) of treatment:
Any treatment related deaths within 30 days of treatment,
and if 2 of the first 5, or 3 of the first 10, 4 of the first 15,
or 5 of the first 20 patients are taken off treatment due to
treatment related toxicity. During the post-procedure per-
iod patients will receive standard of care supportive mea-
sures including analgesics, antiemetics and fluid hydration
and all other medically necessary interventions as needed
when in the best interest of the patient.
The principal investigator will monitor the data and
toxicities to identify trends quarterly, and will be
responsible for revising the protocol as needed to main-
tain safety. The NCI IRB will review submitted adverse
events monthly to also evaluate trends and will require
a follow up plan from the principal investigator when-
ever a trend is identified. A Center for Cancer Research
(CCR) safety monitoring committee will monitor toxicity
trends on this study on at least an annual basis and
report any trends to the NCI IRB and principal investi-
gator. Importantly, the study will be continuously moni-
tored by an external monitoring entity that provides
study auditing and monitoring services under contract
with NIH. The number of patient records monitored is
based on actual accrual.
Statistics
The primary objective of this trial is to determine feasi-
bility, toxicity and tolerability of this treatment after
super-selective continuous arterial infusion of gemcita-
bine in patients with locally-advanced unresectable pan-
creatic cancer. The secondary objectives include:
Conversion rate from unresectable to potentially resect-
able pancreatic cancer, progression free and overall sur-
vival, tumor response rate and to analyze potential
selection criteria for patients who present with locally
advanced pancreatic cancer that might benefit from this
approach. It is expected that a maximum of 15 patients
per year can be accrued onto this trial, and thus accrual
will be completed in approximately 3 years. Allowing for
a very small number of inevaluable patients, the accrual
ceiling will be set at 50 patients.
Progression-free survival will also be evaluated using
Kaplan-Meier curves and a two-tailed log rank test, as a
secondary endpoint. Additionally, a prognostic factor
evaluation using Cox proportional hazards modeling will
take place after the study has concluded in order to iden-
tify factors that are associated with overall or progression-
free survival in patients receiving regional chemotherapy;
this will be interpreted as a secondary endpoint.
Inclusion and Exclusion Criteria
Inclusion criteria
- Histologically or cytologically confirmed locally
advanced pancreatic adenocarcinoma
- Must have evaluable disease by standard radio-
graphic criteria
- Disease should be deemed unresectable
- Patients may be chemo naive or have received
prior chemotherapy (including gemcitabine) and/or
radiation
- Greater than or equal to 18 years of age
- Must be able to understand and sign the Informed
Consent Document
- Clinical performance status of ECOG ≤2
- Life expectancy of greater than three months
- Patients of both genders must be willing to prac-
tice birth control during and for four months after
receiving chemotherapy
- Absolute neutrophil count greater than 1300/mm
3
without the support of filgrastim
- Platelet count greater than 75,000/mm
3
- Hemoglobin greater than 8.0 g/dl
- Serum ALT/AST less or equal to 3 times the
upper limit of normal.
- Serum creatinine less than or equal to 1.8 mg/dl
unless the measured creatinine clearance is greater
than 60 mL/min/1.73 m
2
- Total bilirubin less than or equal to 2 mg/dl
- PT within 2 seconds of the upper limit of normal
or INR≤1.8
- No history of prior/other malignancies within the
2 years prior to enrollment with the exception of
basal cell carcinoma
Exclusion criteria
- Metastatic disease including malignant ascites
- Women of child-bearing potential who are preg-
nant or breastfeeding
- Active systemic infections, coagulation disorders or
other major medical illnesses of the cardiovascular,
respiratory or immune system, myocardial infarction,
heart failure
- Childs B or C cirrhosis or with evidence of severe
portal hypertension by history, endoscopy, or radi-
ologic studies
- Weight less than 40 kg
- Significant ascites, greater than 1000cc in the
absence of peritoneal disease
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Page 5 of 8- Concomitant medical problems that would place
the patient at an unacceptable risk for the procedure
- Need for concurrent chemotherapy
Intervention
Catheter placement will be performed in the Interven-
tional Radiology Section. The catheterization procedure
will be performed as per routine and according to a
three-step strategy; 1) arterial redistribution will be per-
formed as necessary, 2) percutaneous placement of the
indwelling infusion catheter and port, and 3) evaluation
of catheter position and patency and management of
drug distribution.
The purpose of arterial redistribution procedures is to
1) reduce pancreatic arterial supply from multiple
branches to a single (or few) feeding artery(s) for infu-
sion purposes, and 2) occlude non-target arteries that
arise from the chemoinfusion site which supply non-
target intraabdominal organs. In general, pancreatic
head neoplasms will be supplied by the anterior and
posterior pancreaticoduodenal arteries and inferior pan-
creaticoduodenal arteries, whereas the pancreatic body
and cauda tumors are supplied by the dorsal pancreatic
artery, the great pancreatic artery, and the caudal pan-
creatic artery, all branches of the splenic artery. Homma
et al. developed a strategy in which pancreatic arterial
branches are super-selectively embolized, leaving the
great and caudal pancreatic arteries alone arising from
the splenic artery as the chemoinfusion source for any
tumor in the entire pancreas [18].
Following selective catheterization of the superior
mesenteric artery, superior mesenteric arteriography will
be performed to identify accessory or replaced hepatic
vasculature, as well as to assess the patency of the infer-
ior pancreaticoduodenal arcade. If the pancreaticoduo-
denal branches from the gastroduodenal artery are
stenotic or encased by tumor, coil embolization of the
inferior pancreaticoduodenal artery/arcade will be
performed through the origin of this vessel from the
superior mesenteric artery.
Celiac arteriography will then be performed to identify
hepatic and splenic arterial anatomy, followed by selec-
tive gastroduodenal and splenic arteriography to recog-
nize pancreatic supply as well as non-target vessels
supplying the duodenum, or stomach. The anterior and
posterior superior pancreaticoduodenal arteries and the
gastroduodenal arteries will then undergo coil emboliza-
tion. If computed tomography (CT) angiography or
similar study previously demonstrated supply to the tar-
get pancreatic tumor from the dorsal pancreatic artery
(splenic artery origin), then this vessel will be embolized
as well. As a result of the embolization steps, the only
remaining arterial supply to the pancreatic tumor will be
the great pancreatic and caudal pancreatic artery
branches of the splenic artery [19]. The above described
maneuvers will be performed; however it may not always
be possible to perform in all patients due to vascular var-
iation. In these cases a selective infusion will be done via
the most prominent artery supplying the tumor.
Following the selective embolization steps described
above, the tip of the infusion catheter will be placed in
the splenic artery proximal to the great and caudal pan-
creatic arteries. If a different diagnostic catheter is used
for the selective angiography and embolization, catheter
exchange will be performed for the infusion catheter in
routine fashion. Cone bead CT arteriography will be
performed with iodinated contrast injection through the
infusion catheter to confirm opacification of the entire
pancreas. A subcutaneous pocket will be created in the
lower abdominal or lateral thigh soft tissues, and the
trailing end of the infusion catheter will be pulled sub-
cutaneously into the pocket for port attachment.
Post-procedure care and follow up
Patients will be admitted to the NIH Clinical Center and
receive routine post-procedure care. Imaging studies will
confirm catheter placement the evening of and the
morning following the procedure. Initial treatment may
begin the morning following embolization or when all
procedure related toxicities have resolved and imaging
confirms placement of the catheter. During treatment
patients will be monitored for pancreatic-related compli-
cations and any other gastrointestinal, metabolic, hema-
tologic and constitutional symptoms. Prior to discharge
patients will receive instructions regarding subcutaneous
port and catheter care, as well as completion of the
patient diary and potential toxicities.
Patients will undergo evaluation for response at the
end of each course (every 8 weeks) with computed
tomography of the chest, abdomen and pelvis with pan-
creas protocol. Magnetic resonance imaging and posi-
tron emission tomography will be used if indicated.
Response to therapy will be determined using RECIST
criteria and EASL [20,21]. Potential conversion to
resectability following treatment will be determined
using standard radiographic criteria. Patients must be
off chemotherapy for at least 4 weeks and all toxicities
must resolve to grade 1 or less prior to surgery.
Endpoints
Primary Objectives
- To evaluate feasibility and toxicity of intra-arterial
gemcitabine therapy
- To establish the maximum tolerated dose
Secondary Objectives
- To evaluate response rate using RECIST and EASL
criteria
- To determine progression free and overall survival
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to potentially resectable pancreatic cancer
- To analyze potential selection criteria to be used in
future studies for patients who present with margin-
ally unresectable or unresectable locally-advanced
pancreatic cancer
Discussion
The optimal treatment for pancreatic cancer is com-
plete resection followed by adjuvant systemic che-
motherapy. Due to late-stage diagnosis most patients
have limited chance for curative resection, thus novel
approaches for early detection and effective treatment
must be explored. In addition, new approaches that
will convert unresectable locally advanced pancreatic
cancer into a resectable state might result in better
outcome as surgical extirpation provides the only
chance to survive 5 years. In cases which tumors are
detected early enough to allow resection, the choice of
adjuvant chemotherapy is based on the results of a
randomized clinical trial that demonstrated significant
improvement in median overall survival favoring gem-
citabine over observation alone [3]. The addition of
targeted molecular agents or cytotoxic drugs to gemci-
tabine adds little or no clinical benefit to patients with
this disease to date [22,23]. Likewise, although
encouraging, current data are not definitive regarding
the benefit of adjuvant chemoradiotherapy. Therefore,
increasing the rate of resection for patients with pan-
creatic cancer may represent a practical approach to
improve survival for patients currently without a surgi-
cal treatment option. Achieving this goal requires
neoadjuvant therapy that mediates substantial tumor
regression, potentially allowing for complete resection
in previously unresectable patients.
This study offers an innovative approach for locally
advanced unresectable pancreatic cancer: a twenty-four-
hour highly selective intra-arterial infusion of gemcita-
bine. This approach offers two advantages: First, based
on the pharmacodynamics and pharmacokinetics of
gemcitabine, a lower dose infused over prolonged time
will optimally saturate the enzyme responsible for the
conversion of gemcitabine into its two active metabolites
resulting in higher concentrations of intracellular active
gemcitabine, and second, selective intra-arterial delivery
of gemcitabine will avoid systemic toxicity and first pass
degradation of gemcitabine by the small-bowel and the
liver. Local administration of gemcitabine to the pan-
creas has been shown to be safe with low morbidity.
List of abbreviations
CAI: celiac artery infusion - the infusion of chemotherapy via an intra-arterial
catheter positioned within the celiac artery; SAI: selective arterial infusion -
the infusion of chemotherapy via an intra-arterial catheter positioned within
vessels selected for tumor-specific infusion; HAP: hypoxic abdominal
perfusion - the perfusion of chemotherapy utilizing arterial inflow catheters,
venous return catheters and an extra-corporeal circuit; MTD: maximum
tolerated dose - the highest dose that induces dose limiting toxicity in no
more than 1 patient among a cohort of 6 patients; DLT: dose limiting
toxicity - defined as all grade 3 or greater toxicities with the exception of
grade 3 constitutional symptoms that persist for less than 72 hours, grade 3
and 4 myelosuppression (neutrophils and platelets) of less than 5 days
duration, and grade 3 metabolic/laboratory events that are correctable
within 24 hours; ECOG: Eastern Cooperative Oncology Group; AST: aspartate
aminotransferase; ALT: alanine aminotransferase; PT/INR: prothrombin time/
international normalized ratio; RECIST: Response Evaluation Criteria In Solid
Tumors; EASL: European Association for the Study of the Liver
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